

Overview

Useful For

Evaluating neurochondrin-IgG by cell-binding assay using serum from patients presenting with cerebellar and brainstem syndrome

Testing Algorithm

If the indirect immunofluorescence (IFA) pattern suggests neurochondrin, then this test and neurochondrin antibody IFA titer will be performed at an additional charge.

Method Name

Only orderable as a reflex. For more information see:

- DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
- ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
- EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
- MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
- MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
- PCDES / Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum

Cell-Binding Assay (CBA)

NY State Available

Yes

Specimen

Specimen Type

Serum

Specimen Required

Only orderable as a reflex. For more information see:

- DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
- ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
- EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
- MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
- MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
- PCDES / Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum

Specimen Minimum Volume

See Specimen Required

Reject Due To

Gross hemolysis	Reject
Gross lipemia	Reject
Gross icterus	Reject

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	28 days	
	Ambient	72 hours	
	Frozen	28 days	

Clinical & Interpretive

Clinical Information

Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Patients positive for neurochondrin-IgG present with a subacute to chronic cerebellar and brainstem syndrome. Patients respond to long-term immunosuppressive treatment with clinical stabilization or improvement.

Reference Values

- Only orderable as a reflex. For more information see:
- DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
 - ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
 - EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
 - MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
 - MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
 - PCDES / Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum

Negative

Interpretation

A positive result supports a diagnosis of central nervous system autoimmunity. Typical neurological phenotypes encountered include cerebellar ataxia and brainstem encephalitis. A paraneoplastic basis should be considered (uterine cancer in women) though cancers are, generally, not detected. Neurological stabilization or improvement may occur with immune therapy.

Cautions

A negative result does not exclude neurological autoimmunity or cancer

Clinical Reference

Shelly S, Kryzer TJ, Komorowski L, et al: Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2019 Sep 11;6(6):e612. doi: 10.1212/NXI.0000000000000612

Performance

Method Description

Patient specimen is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN; FA_112d-1_A_UK_C13, 02/2019)

PDF Report

No

Day(s) Performed

Monday through Sunday

Report Available

5 to 10 days

Specimen Retention Time

28 days

Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Main Campus

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86255

LOINC® Information

Test Definition: NCDCS

Neurochondrin Antibody, Cell-Binding Assay,
Serum

Test ID	Test Order Name	Order LOINC® Value
NCDCS	Neurochondrin CBA, S	101450-5

Result ID	Test Result Name	Result LOINC® Value
615865	Neurochondrin CBA, S	101450-5